DrugPatentWatch Database Preview
UPTRAVI Drug Profile
see a sample report or, see our see our flat-rate plans
When do Uptravi patents expire, and when can generic versions of Uptravi launch?
This drug has eighty-three patent family members in twenty-eight countries.
The generic ingredient in UPTRAVI is selexipag. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the selexipag profile page.
Summary for UPTRAVI
| International Patents: | 83 |
| US Patents: | 4 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 36 |
| Clinical Trials: | 2 |
| Patent Applications: | 25 |
| DailyMed Link: | UPTRAVI at DailyMed |
Generic Entry Opportunity Date for UPTRAVI
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for UPTRAVI
| Drug Class | Prostacyclin Receptor Agonist |
| Mechanism of Action | Prostacyclin Receptor Agonists |
Synonyms for UPTRAVI
| 144383-EP2289518A1 |
| 144383-EP2292231A1 |
| 2-?[4-?[(5,?6-?DIPHENYLPYRAZINYL)(1-?METHYLETHYL)AMINO]BUTOXY]-?N-?(METHYLSULFONYL)-?ACETAMIDE |
| 2-(4-((5,6-diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)-N-(methylsulfonyl)acetamide |
| 2-(4-((5,6-Diphenylpyrazin-2-yl)(propan-2-yl)amino)butoxy}-n-(methanesulfonyl)acetamide |
| 2-(4-((5,6-Diphenylpyrazinyl)(1-methylethyl)amino)butoxy)-N-(methylsulfonyl)-acetamide |
| 2-[4-[(5,6-Diphenyl-2-pyrazinyl)(1-methylethyl)amino]butoxy]-N-(methylsulfonyl)acetamide |
| 2-[4-[[5,6-di(phenyl)pyrazin-2-yl]-propan-2-ylamino]butoxy]-N-methylsulfonylacetamide |
| 2-{4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}-N-(methanesulfonyl)acetamide |
| 2-{4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}-N-methanesulfonylacetamide |
| 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide |
| 3938AH |
| 475086-01-2 |
| 5EXC0E384L |
| ACT 293987 |
| ACT-293987 |
| ACT293987 |
| AK298890 |
| AKOS024457572 |
| B7378 |
| CHEBI:90844 |
| CHEMBL238804 |
| CS-3774 |
| CTK8F0123 |
| D09994 |
| D0N2SR |
| DB11362 |
| GTPL7552 |
| HE092855 |
| HY-14870 |
| IN2104 |
| KB-79567 |
| KS-00000L89 |
| MFCD10567093 |
| MolPort-009-019-323 |
| NS 304 |
| NS-304 |
| NS-304(Selexipag) |
| QXWZQTURMXZVHJ-UHFFFAOYSA-N |
| RT-014761 |
| SCHEMBL674122 |
| Selexipag |
| Selexipag (JAN/USAN/INN) |
| Selexipag [USAN:INN] |
| UNII-5EXC0E384L |
| Uptravi (TN) |
| ZINC3990451 |
US Patents and Regulatory Information for UPTRAVI
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Actelion Pharms Ltd | UPTRAVI | selexipag | TABLET;ORAL | 207947-007 | Dec 21, 2015 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Actelion Pharms Ltd | UPTRAVI | selexipag | TABLET;ORAL | 207947-006 | Dec 21, 2015 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Actelion Pharms Ltd | UPTRAVI | selexipag | TABLET;ORAL | 207947-008 | Dec 21, 2015 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Actelion Pharms Ltd | UPTRAVI | selexipag | TABLET;ORAL | 207947-005 | Dec 21, 2015 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
see a sample report or, see our see our flat-rate plans
Non-Orange Book US Patents for UPTRAVI
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 9,340,516 | Form-II crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsu- lfonyl) acetamide, method for producing the same, and use thereof | ➤ Sign Up |
| 8,809,334 | Therapeutic compositions containing macitentan | ➤ Sign Up |
| 9,597,331 | Therapeutic compositions containing macitentan | ➤ Sign Up |
| 9,440,931 | Form-III crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsu- lfonyl)acetamide and use thereof | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
see a sample report or, see our see our flat-rate plans
International Patents for UPTRAVI
| Country | Document Number | Estimated Expiration |
|---|---|---|
| China | 104326991 | ➤ Sign Up |
| Spain | 2276931 | ➤ Sign Up |
| Russian Federation | 2011109084 | ➤ Sign Up |
| South Korea | 101678699 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for UPTRAVI
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| /2016 | Austria | ➤ Sign Up | PRODUCT NAME: SELEXIPAG ODER EIN SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/1083 (MITTEILUNG) 20160519 |
| 2016000077 | Germany | ➤ Sign Up | PRODUCT NAME: SELEXIPAG ODER SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/1083/001-010 20160512 |
| C0042 | France | ➤ Sign Up | PRODUCT NAME: SELEXIPAG OU L'UN DE SES SELS; REGISTRATION NO/DATE: EU/1/15/1083 20160519 |
| 266 | Luxembourg | ➤ Sign Up | PRODUCT NAME: SELEXIPAG OU UN SEL DE CELUI-CI; FIRST REGISTRATION DATE: 20160519 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
